UCSF

Tagged: pharmacokinetics

Data for a difference

Low-cost drug treatments can cure TB and malaria. Why, then, do these diseases claim so many lives?

Aweeka study details impact of HIV drugs on malaria treatment in children

Sub-Saharan Africa is home to a billion people and to overlapping health burdens, including the world’s highest rates of both malaria and HIV infection.

30th Annual Course on Pharmacokinetics for Pharmaceutical Scientists

Pharmacokinetics for Pharmaceutical Scientists is an annual course, now in its 30th year. 

Research: pediatric meningitis dosing; cancer drug resistance; gene-testing economics

Computer models provide optimal dosing for pediatric TB meningitis

Benet receives Remington Honor Medal, highest award in pharmacy

UCSF School of Pharmacy faculty member Leslie Benet, PhD, has been named the 2016 recipient of the Remington Honor Medal, the highest honor bestowed by the American Pharmacists Association (APhA). He will be officially recognized during the APhA Annual Meeting and Exposition in Baltimore, MD, March 4–7, 2016.

Giacomini to lead largest study of genetic, ethnic differences in effectiveness of leading diabetes drug

In people with type 2 diabetes, the body is less able to use the hormone insulin to regulate blood sugar. The disease affects 350 million patients globally—including 29 million in the United States, where it is the leading cause of blindness, kidney failure, and non-accident-related amputations.

Yang study demonstrates simulator to study antibiotic dosing against biofilms

Nearly every human bacterial infection—including some of the most serious, life threatening, and costly to treat—can take the form of a biofilm, in which bacteria aggregate into structured communities that enclose themselves within a secreted slime.

Study discovers why leading gout medication is ineffective for many

Allopurinol, the first-choice medication for treating gout—an excruciatingly painful condition that is the most common form of inflammatory arthritis, afflicts more than eight million Americans, and is on the rise worldwide—is not fully effective in more than half of patients.

C. Anthony Hunt, PhD

Hunt
Professor

I am a theoretical systems pharmacologist who develops advanced simulation methods to improve multiscale mechanistic explanations of complex phenomena in the presence and absence of therapeutic interventions.

Katherine Yang, PharmD, MPH

Yang
Professor

My research focuses on pharmacodynamic optimization for the treatment of multi-drug resistant organisms such as Pseudomonas aeruginosa. I am particularly interested in dosing strategies to combat biofilm-mediated infections such as cystic fibrosis.

Pages